{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,13]],"date-time":"2026-11-13T22:45:36Z","timestamp":1794609936508,"version":"4.9.1"},"reference-count":49,"publisher":"Bentham Science Publishers Ltd.","issue":"4","content-domain":{"domain":["eurekaselect.com"],"crossmark-restriction":true},"short-container-title":["CN"],"published-print":{"date-parts":[[2025,4]]},"abstract":"<jats:sec>\n                    <jats:title>Background:<\/jats:title>\n                    <jats:p>Co-occurrence of substance use disorders is frequent in patients with mental\nhealth disorders is a condition known as \u201cdual diagnosis\u201d. The use of substances worsens the prognosis\nand lowers the quality of life of psychiatric patients. It also increases the risk of hospitalization and\nsuicide rate.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Objectives:<\/jats:title>\n                    <jats:p>To assess the effects of aripiprazole therapy on substance use and other psychiatric outcomes\nin dually diagnosed patients.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods:<\/jats:title>\n                    <jats:p>We performed a systematic review conducted on 3 databases PUBMED, SCOPUS, and\nWeb of Science, selecting original studies and analyzing the impact of aripiprazole therapy on dually\ndiagnosed patients. Six hundred and fifty-five articles were founded and, after removing duplicates\n(n = 274) and applying the exclusion criteria, 12 articles were included in our systematic review.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results:<\/jats:title>\n                    <jats:p>12 studies were included, among which 6 were Randomized Controlled Trials. The Most frequent\npsychiatric diagnosis were schizoaffective disorders, schizophrenia, and bipolar disorders. Alcohol\nand cocaine use disorders were the most used substances. Eleven studies showed a clinical improvement\nafter aripiprazole treatment. 8 studies evaluated craving and found a significant reduction\nafter treatment with aripiprazole. No definitive conclusions can be drawn on substance usage and\nmaintenance of abstinence.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion:<\/jats:title>\n                    <jats:p>The present findings suggest aripiprazole may be associated with reducing substance craving\nand improving depression, psychosis, and schizoaffective disorders in dually diagnosed patients.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.2174\/1570159x23666241023115252","type":"journal-article","created":{"date-parts":[[2024,10,25]],"date-time":"2024-10-25T02:44:01Z","timestamp":1729824241000},"page":"404-411","update-policy":"https:\/\/doi.org\/10.2174\/bsp_crossmark_policy","source":"Crossref","is-referenced-by-count":7,"title":["Oral and Long-acting Injectable Aripiprazole in Severe Mental Illness and Substance Use Disorder Comorbidity: An Updated Systematic Review"],"prefix":"10.2174","volume":"23","author":[{"given":"Mario","family":"Santorelli","sequence":"first","affiliation":[{"name":"School of Medicine and Surgery, University of Milano Bicocca, Monza 20900, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrea","family":"Miuli","sequence":"additional","affiliation":[{"name":"Department of Neuroscience,\nImaging, and Clinical Sciences, University G. d'Annunzio of Chieti-Pescara, Chieti, Italy"},{"name":"Department of Mental\nHealth, ASL Lanciano-Vasto-Chieti, Chieti, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mauro","family":"Pettorruso","sequence":"additional","affiliation":[{"name":"Department of Neuroscience,\nImaging, and Clinical Sciences, University G. d'Annunzio of Chieti-Pescara, Chieti, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francesco","family":"Di Carlo","sequence":"additional","affiliation":[{"name":"Department of Neuroscience,\nImaging, and Clinical Sciences, University G. d'Annunzio of Chieti-Pescara, Chieti, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Domenico","family":"De Berardis","sequence":"additional","affiliation":[{"name":"National Health Service, Department of Mental Health, ASL 4,\nTeramo 64100, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stefano L.","family":"Sensi","sequence":"additional","affiliation":[{"name":"Department of Neuroscience,\nImaging, and Clinical Sciences, University G. d'Annunzio of Chieti-Pescara, Chieti, Italy"},{"name":"Molecular Neurology Unit, Center for Advanced Studies and Technology - CAST, Institute for\nAdvanced Biomedical Technology-ITAB University G. d'Annunzio, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giovanni","family":"Martinotti","sequence":"additional","affiliation":[{"name":"Department of Neuroscience,\nImaging, and Clinical Sciences, University G. d'Annunzio of Chieti-Pescara, Chieti, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Massimo","family":"Clerici","sequence":"additional","affiliation":[{"name":"Department of Surgery and Interdisciplinary\nMedicine, University of Milano-Bicocca, Monza 20900, Italy"},{"name":"Department of Mental Health, Azienda Ospedaliera San\nGerardo, Monza 20900, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Massimo","family":"di Giannantonio","sequence":"additional","affiliation":[{"name":"Department of Neuroscience,\nImaging, and Clinical Sciences, University G. d'Annunzio of Chieti-Pescara, Chieti, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"965","reference":[{"key":"ref=1","doi-asserted-by":"publisher","first-page":"78","DOI":"10.1016\/j.schres.2017.04.016","volume":"194","author":"Khokhar J.Y.","year":"2018","unstructured":"Khokhar J.Y.; Dwiel L.L.; Henricks A.M.; Doucette W.T.; Green A.I.; The link between schizophrenia and substance use disorder: A unifying hypothesis. Schizophr Res  2018,194,78-85","journal-title":"Schizophr Res"},{"key":"ref=2","doi-asserted-by":"publisher","first-page":"550","DOI":"10.1111\/j.1447-0349.2012.00833.x","volume":"21","author":"Edward K.L.","year":"2012","unstructured":"Edward K.L.; Robins A.; Dual diagnosis, as described by those who experience the disorder: Using the Internet as a source of data. Int J Ment Health Nurs  2012,21(6),550-559","journal-title":"Int J Ment Health Nurs"},{"key":"ref=3","doi-asserted-by":"publisher","first-page":"288","DOI":"10.1016\/j.jad.2020.01.141","volume":"266","author":"Hunt G.E.","year":"2020","unstructured":"Hunt G.E.; Malhi G.S.; Lai H.M.X.; Cleary M.; Prevalence of comorbid substance use in major depressive disorder in community and clinical settings, 1990-2019: Systematic review and meta-analysis. J Affect Disord  2020,266,288-304","journal-title":"J Affect Disord"},{"key":"ref=4","doi-asserted-by":"publisher","first-page":"330","DOI":"10.1016\/j.amjmed.2005.01.007","volume":"118","author":"Sullivan L.E.","year":"2005","unstructured":"Sullivan L.E.; Fiellin D.A.; O\u2019Connor P.G.; The prevalence and impact of alcohol problems in major depression: A systematic review. Am J Med  2005,118(4),330-341","journal-title":"Am J Med"},{"key":"ref=5","doi-asserted-by":"publisher","first-page":"865","DOI":"10.4088\/JCP.10m06673","volume":"73","author":"Blanco C.","year":"2012","unstructured":"Blanco C.; Alegr\u00eda A.A.; Liu S.M.; Secades-Villa R.; Sugaya L.; Davies C.; Nunes E.V.; Differences among major depressive disorder with and without co-occurring substance use disorders and substance-induced depressive disorder: Results from the National Epidemiologic Survey on Alcohol and Related Conditions. J Clin Psychiatry  2012,73(6),865-873","journal-title":"J Clin Psychiatry"},{"key":"ref=6","doi-asserted-by":"publisher","first-page":"4","DOI":"10.1007\/s11920-014-0544-y","volume":"17","author":"Vorspan F.","year":"2015","unstructured":"Vorspan F.; Mehtelli W.; Dupuy G.; Bloch V.; L\u00e9pine J.P.; Anxiety and substance use disorders: Co-occurrence and clinical issues. Curr Psychiatry Rep  2015,17(2),4","journal-title":"Curr Psychiatry Rep"},{"key":"ref=7","doi-asserted-by":"publisher","first-page":"E01","DOI":"10.3810\/pgm.2008.07.1802","volume":"120","author":"Clay S.","year":"2008","unstructured":"Clay S.; Allen J.; Parran T.; A review of addiction. Postgrad Med  2008,120(2),E01-E07","journal-title":"Postgrad Med"},{"key":"ref=8","doi-asserted-by":"publisher","first-page":"1162","DOI":"10.1111\/j.1476-5381.2011.01386.x","volume":"164","author":"Jones C.A.","year":"2011","unstructured":"Jones C.A.; Watson D.J.G.; Fone K.C.F.; Animal models of schizophrenia. Br J Pharmacol  2011,164(4),1162-1194","journal-title":"Br J Pharmacol"},{"key":"ref=9","doi-asserted-by":"publisher","first-page":"1914","DOI":"10.1038\/npp.2014.39","volume":"39","author":"Trost S.","year":"2014","unstructured":"Trost S.; Diekhof E.K.; Zvonik K.; Lewandowski M.; Usher J.; Keil M.; Zilles D.; Falkai P.; Dechent P.; Gruber O.; Disturbed anterior prefrontal control of the mesolimbic reward system and increased impulsivity in bipolar disorder. Neuropsychopharmacology  2014,39(8),1914-1923","journal-title":"Neuropsychopharmacology"},{"key":"ref=10","doi-asserted-by":"publisher","first-page":"1229","DOI":"10.1111\/cns.13230","volume":"25","author":"Spano M.C.","year":"2019","unstructured":"Spano M.C.; Lorusso M.; Pettorruso M.; Zoratto F.; Di Giuda D.; Martinotti G.; Giannantonio M.; Anhedonia across borders: Transdiagnostic relevance of reward dysfunction for noninvasive brain stimulation endophenotypes. CNS Neurosci Ther  2019,25(11),1229-1236","journal-title":"CNS Neurosci Ther"},{"key":"ref=11","doi-asserted-by":"publisher","first-page":"194","DOI":"10.1097\/YCO.0b013e328351a3e0","volume":"25","author":"Murthy P.","year":"2012","unstructured":"Murthy P.; Chand P.; Treatment of dual diagnosis disorders. Curr Opin Psychiatry  2012,25(3),194-200","journal-title":"Curr Opin Psychiatry"},{"key":"ref=12","doi-asserted-by":"publisher","first-page":"841","DOI":"10.4088\/JCP.v62n1101","volume":"62","author":"Stahl S.M.","year":"2001","unstructured":"Stahl S.M.; Dopamine system stabilizers, aripiprazole, and the next generation of antipsychotics, part 1, \u201cGoldilocks\u201d actions at dopamine receptors. J Clin Psychiatry  2001,62(11),841-842","journal-title":"J Clin Psychiatry"},{"key":"ref=13","doi-asserted-by":"publisher","first-page":"137","DOI":"10.1016\/S0014-2999(02)01532-7","volume":"441","author":"Jordan S.","year":"2002","unstructured":"Jordan S.; Koprivica V.; Chen R.; Tottori K.; Kikuchi T.; Altar C.A.; The antipsychotic aripiprazole is a potent, partial agonist at the human 5-HT1A receptor. Eur J Pharmacol  2002,441(3),137-140","journal-title":"Eur J Pharmacol"},{"key":"ref=14","doi-asserted-by":"publisher","first-page":"1135","DOI":"10.1021\/acschemneuro.7b00087","volume":"8","author":"Casey A.B.","year":"2017","unstructured":"Casey A.B.; Canal C.E.; Classics in chemical neuroscience: Aripiprazole. ACS Chem Neurosci  2017,8(6),1135-1146","journal-title":"ACS Chem Neurosci"},{"key":"ref=15","doi-asserted-by":"publisher","first-page":"1215","DOI":"10.1007\/s00228-018-2498-1","volume":"74","author":"Ribeiro E.L.A.","year":"2018","unstructured":"Ribeiro E.L.A.; de Mendon\u00e7a Lima T.; Vieira M.E.B.; Storpirtis S.; Aguiar P.M.; Efficacy and safety of aripiprazole for the treatment of schizophrenia: An overview of systematic reviews. Eur J Clin Pharmacol  2018,74(10),1215-1233","journal-title":"Eur J Clin Pharmacol"},{"key":"ref=16","doi-asserted-by":"publisher","first-page":"97","DOI":"10.1111\/bdi.12609","volume":"20","author":"Yatham L.N.","year":"2018","unstructured":"Yatham L.N.; Kennedy S.H.; Parikh S.V.; Schaffer A.; Bond D.J.; Frey B.N.; Sharma V.; Goldstein B.I.; Rej S.; Beaulieu S.; Alda M.; MacQueen G.; Milev R.V.; Ravindran A.; O\u2019Donovan C.; McIntosh D.; Lam R.W.; Vazquez G.; Kapczinski F.; McIntyre R.S.; Kozicky J.; Kanba S.; Lafer B.; Suppes T.; Calabrese J.R.; Vieta E.; Malhi G.; Post R.M.; Berk M.; Canadian network for mood and anxiety treatments (CANMAT) and international society for bipolar disorders (ISBD) 2018 guidelines for the management of patients with bipolar disorder. Bipolar Disord  2018,20(2),97-170","journal-title":"Bipolar Disord"},{"key":"ref=17","doi-asserted-by":"publisher","first-page":"1375","DOI":"10.1016\/j.pnpbp.2008.02.008","volume":"32","author":"Wobrock T.","year":"2008","unstructured":"Wobrock T.; Soyka M.; Pharmacotherapy of schizophrenia with comorbid substance use disorder - Reviewing the evidence and clinical recommendations. Prog Neuropsychopharmacol Biol Psychiatry  2008,32(6),1375-1385","journal-title":"Prog Neuropsychopharmacol Biol Psychiatry"},{"key":"ref=18","doi-asserted-by":"publisher","first-page":"351","DOI":"10.1038\/nrn.2016.39","volume":"17","author":"Wolf M.E.","year":"2016","unstructured":"Wolf M.E.; Synaptic mechanisms underlying persistent cocaine craving. Nat Rev Neurosci  2016,17(6),351-365","journal-title":"Nat Rev Neurosci"},{"key":"ref=19","doi-asserted-by":"publisher","first-page":"84","DOI":"10.1017\/S1092852920001479","volume":"26","author":"Martinotti G.","year":"2021","unstructured":"Martinotti G.; De Risio L.; Vannini C.; Schifano F.; Pettorruso M.; Di Giannantonio M.; Substance-related exogenous psychosis: A postmodern syndrome. CNS Spectr  2021,26(1),84-91","journal-title":"CNS Spectr"},{"key":"ref=20","doi-asserted-by":"publisher","first-page":"233","DOI":"10.1177\/0963689718811060","volume":"28","author":"Wang S.","year":"2019","unstructured":"Wang S.; Historical review: Opiate addiction and opioid receptors. Cell Transplant  2019,28(3),233-238","journal-title":"Cell Transplant"},{"key":"ref=21","doi-asserted-by":"publisher","first-page":"872","DOI":"10.1111\/adb.12205","volume":"20","author":"Li X.","year":"2015","unstructured":"Li X.; Caprioli D.; Marchant N.J.; Recent updates on incubation of drug craving: A mini-review. Addict Biol  2015,20(5),872-876","journal-title":"Addict Biol"},{"key":"ref=22","doi-asserted-by":"publisher","first-page":"1403","DOI":"10.1176\/appi.ajp.162.8.1403","volume":"162","author":"Kalivas P.W.","year":"2005","unstructured":"Kalivas P.W.; Volkow N.D.; The neural basis of addiction: A pathology of motivation and choice. Am J Psychiatry  2005,162(8),1403-1413","journal-title":"Am J Psychiatry"},{"key":"ref=23","doi-asserted-by":"publisher","first-page":"245","DOI":"10.15288\/jsad.2019.80.245","volume":"80","author":"Grodin E.N.","year":"2019","unstructured":"Grodin E.N.; Courtney K.E.; Ray L.A.; Drug-induced craving for methamphetamine is associated with neural methamphetamine cue reactivity. J Stud Alcohol Drugs  2019,80(2),245-251","journal-title":"J Stud Alcohol Drugs"},{"key":"ref=24","doi-asserted-by":"publisher","first-page":"729","DOI":"10.1176\/appi.ajp.2018.17101174","volume":"175","author":"Volkow N.D.","year":"2018","unstructured":"Volkow N.D.; Boyle M.; Neuroscience of addiction: Relevance to prevention and treatment. Am J Psychiatry  2018,175(8),729-740","journal-title":"Am J Psychiatry"},{"key":"ref=25","doi-asserted-by":"publisher","first-page":"2165","DOI":"10.1016\/j.neuron.2021.05.002","volume":"109","author":"Pribiag H.","year":"2021","unstructured":"Pribiag H.; Shin S.; Wang E.H.J.; Sun F.; Datta P.; Okamoto A.; Guss H.; Jain A.; Wang X.Y.; De Freitas B.; Honma P.; Pate S.; Lilascharoen V.; Li Y.; Lim B.K.; Ventral pallidum DRD3 potentiates a pallido-habenular circuit driving accumbal dopamine release and cocaine seeking. Neuron  2021,109(13),2165-2182.e10","journal-title":"Neuron"},{"key":"ref=26","doi-asserted-by":"publisher","first-page":"657","DOI":"10.1097\/JCP.0000000000000789","volume":"37","author":"Beresford T.","year":"2017","unstructured":"Beresford T.; Buchanan J.; Thumm E.B.; Emrick C.; Weitzenkamp D.; Ronan P.J.; Late reduction of cocaine cravings in a randomized, double-blind trial of aripiprazole vs. perphenazine in schizophrenia and comorbid cocaine dependence. J Clin Psychopharmacol  2017,37(6),657-663","journal-title":"J Clin Psychopharmacol"},{"key":"ref=27","doi-asserted-by":"publisher","first-page":"1645","DOI":"10.2147\/NDT.S171002","volume":"14","author":"Cuomo I.","year":"2018","unstructured":"Cuomo I.; Kotzalidis G.D.; de Persis S.; Piacentino D.; Perrini F.; Amici E.; De Filippis S.; Head-to-head comparison of 1-year aripiprazole long-acting injectable (LAI) versus paliperidone LAI in comorbid psychosis and substance use disorder: Impact on clinical status, substance craving, and quality of life. Neuropsychiatr Dis Treat  2018,14,1645-1656","journal-title":"Neuropsychiatr Dis Treat"},{"key":"ref=28","doi-asserted-by":"publisher","first-page":"10","DOI":"10.3109\/00952990.2013.861843","volume":"40","author":"Farnia V.","year":"2014","unstructured":"Farnia V.; Shakeri J.; Tatari F.; Juibari T.A.; Yazdchi K.; Bajoghli H.; Brand S.; Abdoli N.; Aghaei A.; Randomized controlled trial of aripiprazole versus risperidone for the treatment of amphetamine-induced psychosis. Am J Drug Alcohol Abuse  2014,40(1),10-15","journal-title":"Am J Drug Alcohol Abuse"},{"key":"ref=29","doi-asserted-by":"publisher","first-page":"139","DOI":"10.1177\/0269881112472563.Adjunctive","volume":"176","author":"Hyun Han D.","year":"2017","unstructured":"Hyun Han D.; Mi Kim S.; Eun Choi J.; Joon Min K.; Renshawm P.F.; Adjunctive aripiprazole therapy with escitalopram in patients with co-morbid major depressive disorder and alcohol dependence: Clinical and neuroimaging evidence Doug. Physiol Behav  2017,176(12),139-148","journal-title":"Physiol Behav"},{"key":"ref=30","doi-asserted-by":"publisher","first-page":"131","DOI":"10.3109\/13651501.2012.667116","volume":"17","author":"Sulaiman A.H.","year":"2013","unstructured":"Sulaiman A.H.; Gill J.S.; Said M.A.; Zainal N.Z.; Hussein H.M.; Guan N.C.; A randomized, placebo-controlled trial of aripiprazole for the treatment of methamphetamine dependence and associated psychosis. Int J Psychiatry Clin Pract  2013,17(2),131-138","journal-title":"Int J Psychiatry Clin Pract"},{"key":"ref=31","doi-asserted-by":"publisher","first-page":"513","DOI":"10.1080\/10550887.2021.1905589","volume":"39","author":"Skryabin V.Y.","year":"2021","unstructured":"Skryabin V.Y.; Vinnikova M.A.; Ezhkova E.V.; Titkov M.S.; Bulatova R.A.; Atypical antipsychotics in the treatment of patients with a dual diagnosis of schizophrenia spectrum disorders and substance use disorders: The results of a randomized comparative study. J Addict Dis  2021,39(4),513-525","journal-title":"J Addict Dis"},{"key":"ref=32","doi-asserted-by":"publisher","first-page":"363","DOI":"10.1097\/01.jcp.0000169419.38899.5b","volume":"25","author":"Beresford T.P.","year":"2005","unstructured":"Beresford T.P.; Clapp L.; Martin B.; Wiberg J.L.; Alfers J.; Beresford H.F.; Aripiprazole in schizophrenia with cocaine dependence: A pilot study. J Clin Psychopharmacol  2005,25(4),363-366","journal-title":"J Clin Psychopharmacol"},{"key":"ref=33","doi-asserted-by":"publisher","first-page":"119","DOI":"10.1080\/08897077.2013.814615","volume":"35","author":"Bruno A.","year":"2014","unstructured":"Bruno A.; Romeo V.M.; Pandolfo G.; Scimeca G.; Zoccali R.A.; Muscatello M.R.A.; Aripiprazole plus topiramate in opioid-dependent patients with schizoaffective disorder: An 8-week, open-label, uncontrolled, preliminary study. Subst Abus  2014,35(2),119-121","journal-title":"Subst Abus"},{"key":"ref=34","doi-asserted-by":"publisher","first-page":"83","DOI":"10.1080\/15504260802620210","volume":"5","author":"McRae-Clark A.L.","year":"2009","unstructured":"McRae-Clark A.L.; Verduin M.L.; Tolliver B.K.; Carter R.E.; Wahlquist A.E.; Brady K.T.; Cluver J.S.; Anderson S.; An open-label trial of aripiprazole treatment in dual diagnosis individuals: Safety and efficacy. J Dual Diagn  2009,5(1),83-96","journal-title":"J Dual Diagn"},{"key":"ref=35","doi-asserted-by":"publisher","first-page":"756","DOI":"10.4088\/JCP.v66n0613","volume":"66","author":"Brown E.S.","year":"2005","unstructured":"Brown E.S.; Jeffress J.; Liggin J.D.M.; Garza M.; Beard L.; Switching outpatients with bipolar or schizoaffective disorders and substance abuse from their current antipsychotic to aripiprazole. J Clin Psychiatry  2005,66(6),756-760","journal-title":"J Clin Psychiatry"},{"key":"ref=36","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1007\/s40801-020-00178-8","volume":"7","author":"Szerman N.","year":"2020","unstructured":"Szerman N.; Basurte-Villamor I.; Vega P.; Martinez-Raga J.; Parro-Torres C.; Cambra Almerge J.; Grau-L\u00f3pez L.; De Matteis M.; Arias F.; Once-monthly long-acting injectable aripiprazole for the treatment of patients with schizophrenia and co-occurring] substance use disorders: A multicentre, observational study. Drugs Real World Outcomes  2020,7(1),75-83","journal-title":"Drugs Real World Outcomes"},{"key":"ref=37","doi-asserted-by":"publisher","first-page":"393","DOI":"10.1080\/00952990701313660","volume":"33","author":"Martinotti G.","year":"2007","unstructured":"Martinotti G.; Nicola M.D.; Janiri L.; Efficacy and safety of aripiprazole in alcohol dependence. Am J Drug Alcohol Abuse  2007,33(3),393-401","journal-title":"Am J Drug Alcohol Abuse"},{"key":"ref=38","doi-asserted-by":"publisher","first-page":"282","DOI":"10.1177\/0269881112472563","volume":"27","author":"Han D.H.","year":"2013","unstructured":"Han D.H.; Kim S.M.; Choi J.E.; Min K.J.; Renshaw P.F.; Adjunctive aripiprazole therapy with escitalopram in patients with co-morbid major depressive disorder and alcohol dependence: Clinical and neuroimaging evidence. J Psychopharmacol  2013,27(3),282-291","journal-title":"J Psychopharmacol"},{"key":"ref=39","doi-asserted-by":"publisher","first-page":"83","DOI":"10.2147\/NDT.S171002","volume":"7","author":"McRae-Clark A.L.","year":"2020","unstructured":"McRae-Clark A.L.; Efficacy and safety of aripiprazole in alcohol dependence. Drugs Real World Outcomes  2020,7(1),83-96","journal-title":"Drugs Real World Outcomes"},{"key":"ref=40","doi-asserted-by":"publisher","first-page":"649","DOI":"10.1016\/j.conb.2013.05.001","volume":"23","author":"Sinha R.","year":"2013","unstructured":"Sinha R.; The clinical neurobiology of drug craving. Curr Opin Neurobiol  2013,23(4),649-654","journal-title":"Curr Opin Neurobiol"},{"key":"ref=41","doi-asserted-by":"publisher","first-page":"3113","DOI":"10.1098\/rstb.2008.0094","author":"Koob G.F.","unstructured":"Koob G.F.; Le Moal M.; Se V.;   ,3113-3123"},{"key":"ref=42","doi-asserted-by":"publisher","first-page":"2977","DOI":"10.1523\/JNEUROSCI.22-07-02977.2002","volume":"22","author":"Caine S.B.","year":"2002","unstructured":"Caine S.B.; Negus S.S.; Mello N.K.; Patel S.; Bristow L.; Kulagowski J.; Vallone D.; Saiardi A.; Borrelli E.; Role of dopamine D2-like receptors in cocaine self-administration: Studies with D2 receptor mutant mice and novel D2 receptor antagonists. J Neurosci  2002,22(7),2977-2988","journal-title":"J Neurosci"},{"key":"ref=43","doi-asserted-by":"publisher","first-page":"275","DOI":"10.3389\/fpsyt.2020.00275","volume":"11","author":"Miuli A.","year":"2020","unstructured":"Miuli A.; Pettorruso M.; Romanelli E.; Stigliano G.; Di Giuda D.; De-Giorgio F.; Martinotti G.; di Giannantonio M.; Does DRD2 Taq1A mediate aripiprazole-induced gambling disorder? a pharmacogenetic hypothesis. Front Psychiatry  2020,11,275","journal-title":"Front Psychiatry"},{"key":"ref=44","doi-asserted-by":"publisher","first-page":"9595","DOI":"10.1523\/JNEUROSCI.22-21-09595.2002","volume":"22","author":"Vorel S.R.","year":"2002","unstructured":"Vorel S.R.; Ashby C.R.; Paul M.; Liu X.; Hayes R.; Hagan J.J.; Middlemiss D.N.; Stemp G.; Gardner E.L.; Dopamine D3 receptor antagonism inhibits cocaine-seeking and cocaine-enhanced brain reward in rats. J Neurosci  2002,22(21),9595-9603","journal-title":"J Neurosci"},{"key":"ref=45","doi-asserted-by":"publisher","first-page":"e0252516","DOI":"10.1371\/journal.pone.0252516","volume":"16","author":"Wolfschlag M.","year":"2021","unstructured":"Wolfschlag M.; H\u00e5kansson A.; Increased risk for developing gambling disorder under the treatment with pramipexole, ropinirole, and aripiprazole: A nationwide register study in Sweden. PLoS One  2021,16(6),e0252516","journal-title":"PLoS One"},{"key":"ref=46","doi-asserted-by":"publisher","first-page":"481","DOI":"10.1016\/j.neubiorev.2020.09.034","volume":"119","author":"Pettorruso M.","year":"2020","unstructured":"Pettorruso M.; Zoratto F.; Miuli A.; De Risio L.; Santorelli M.; Pierotti A.; Martinotti G.; Adriani W.; di Giannantonio M.; Exploring dopaminergic transmission in gambling addiction: A systematic translational review. Neurosci Biobehav Rev  2020,119,481-511","journal-title":"Neurosci Biobehav Rev"},{"key":"ref=47","doi-asserted-by":"publisher","first-page":"1","DOI":"10.4088\/JCP.15032su1","volume":"77","author":"Correll C.U.","year":"2016","unstructured":"Correll C.U.; The use of long-acting injectable antipsychotics in schizophrenia: Evaluating the evidence. J Clin Psychiatry  2016,77(suppl 3),1-24","journal-title":"J Clin Psychiatry"},{"key":"ref=48","doi-asserted-by":"publisher","first-page":"220","DOI":"10.1016\/j.schres.2016.07.018","volume":"176","author":"Misawa F.","year":"2016","unstructured":"Misawa F.; Kishimoto T.; Hagi K.; Kane J.M.; Correll C.U.; Safety and tolerability of long-acting injectable versus oral antipsychotics: A meta-analysis of randomized controlled studies comparing the same antipsychotics. Schizophr Res  2016,176(2-3),220-230","journal-title":"Schizophr Res"},{"key":"ref=49","doi-asserted-by":"publisher","first-page":"808002","DOI":"10.3389\/fpsyt.2021.808002","volume":"12","author":"Coles A.S.","year":"2021","unstructured":"Coles A.S.; Knezevic D.; George T.P.; Correll C.U.; Kane J.M.; Castle D.; Long-acting injectable antipsychotic treatment in schizophrenia and co-occurring substance use disorders: A systematic review. Front Psychiatry  2021,12,808002","journal-title":"Front Psychiatry"}],"container-title":["Current Neuropharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.eurekaselect.com\/article\/download?doi=10.2174\/1570159X23666241023115252","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.eurekaselect.com\/235606\/article","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.eurekaselect.com\/article\/download?doi=10.2174\/1570159X23666241023115252","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,1,30]],"date-time":"2025-01-30T05:49:18Z","timestamp":1738216158000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.eurekaselect.com\/235606\/article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,4]]},"references-count":49,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2025,4]]}},"alternative-id":["LiveAll1"],"URL":"https:\/\/doi.org\/10.2174\/1570159x23666241023115252","relation":{},"ISSN":["1570-159X"],"issn-type":[{"value":"1570-159X","type":"print"}],"subject":[],"published":{"date-parts":[[2025,4]]},"assertion":[{"value":"Peer Reviewed","order":0,"name":"review_status","label":"Review Status","group":{"name":"peer_review_details","label":"Peer Review Details"}},{"value":"Single blind","order":1,"name":"review_process","label":"Review Process","group":{"name":"peer_review_details","label":"Peer Review Details"}},{"value":"Checked with iThenticate","order":0,"name":"screening_status","label":"Screening Status","group":{"name":"plagiarism_screening","label":"Plagiarism Screening"}},{"value":"2022-07-14","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2022-09-09","order":1,"name":"revised","label":"Revised","group":{"name":"publication_history","label":"Publication History"}},{"value":"2022-09-16","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2024-12-31","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}